PFS Partners’s Gossamer Bio GOSS Stock Holding History

PFS Partners’s Portfolio GOSS Stock Details GOSS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-50	Closed	-$55	–	510
2025 Q1	$55	Sell	50 -13	-21%	-$15	﹤0.01%	436
2024 Q4	$57	Sell	63 -65	-51%	-$56	﹤0.01%	442
2024 Q3	$127	Sell	128 -2	-2%	-$2	﹤0.01%	442
2024 Q2	$118	Hold	130	–	–	﹤0.01%	433
2024 Q1	$154	Hold	130	–	–	﹤0.01%	452
2023 Q4	$119	Sell	130 -10	-7%	-$7	﹤0.01%	455
2023 Q3	$117	Sell	140 -10	-7%	-$12	﹤0.01%	458
2023 Q2	$180	Hold	150	–	–	﹤0.01%	472
2023 Q1	$189	Sell	150 -5	-3%	-$10	﹤0.01%	380
2022 Q4	$337	Sell	155 -13	-8%	-$107	﹤0.01%	363
2022 Q3	$2.01K	Hold	168	–	–	﹤0.01%	305
2022 Q2	$1.41K	Hold	168	–	–	﹤0.01%	322
2022 Q1	$1.46K	Sell	168 -4	-2%	-$39	﹤0.01%	323
2021 Q4	$1.95K	Buy	+172	New	+$2.04K	﹤0.01%	310

Other funds holding GOSS

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PFS Partners's GOSS Position: Q2 2025 in Review

PFS Partners sold out of Gossamer Bio (GOSS) in Q2 2025, closing a stake of 50 shares — an estimated $55 sold.

PFS Partners first reported a position in GOSS in Q4 2021 and held it in 14 quarters. The position peaked at $2.01K in Q3 2022. 123 funds tracked by Wall St. Rank hold GOSS as of Q2 2025.

PFS Partners reported no remaining Gossamer Bio position as of Q2 2025 after selling out during the quarter.
PFS Partners sold 50 Gossamer Bio shares in Q2 2025, an estimated $55.
PFS Partners first reported a position in Gossamer Bio in Q4 2021 and held it in 14 quarters.
PFS Partners's Gossamer Bio position peaked at $2.01K in Q3 2022.
123 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2025.

Based on PFS Partners's 13F filing for Q2 2025, filed 16 Jul 2025.